Plain-English translation of NCT06454188 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a study testing whether a medication called upadacitinib can help people with psoriatic arthritis (a condition that causes joint inflammation and skin problems) when it also affects the spine. About 100 people will take part, and half will receive the medication while the other half receive a placebo (a pill with no active ingredients) for 12 weeks. Researchers want to see if this treatment can reduce pain, inflammation, and other symptoms related to spine involvement in psoriatic arthritis.
Psoriatic arthritis can be very painful, especially when it affects the spine and lower back. Many patients don't respond well enough to common pain relievers like ibuprofen or naproxen. This trial exists to see whether this medication might offer better relief for people in this situation.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to take either the new medication or a placebo tablet once per day for 12 weeks. You'll attend study visits where doctors will check how you're doing, ask about your symptoms, and possibly do blood tests or imaging. Throughout the 12 weeks, you'll keep track of your pain and other symptoms so researchers can see whether the medication helps compared to the placebo.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States
Canada